LONDON and AMSTERDAM, Sept. 6,
2016 /PRNewswire/ -- Royal Philips (NYSE: PHG, AEX:
PHIA) today announced preliminary results of an independent,
multi-center Home Oxygen Therapy – Home Mechanical Ventilation
(HOT-HMV) study carried out by respiratory experts at St Thomas'
Hospital in London. Philips'
pioneering work in chronic obstructive pulmonary disease (COPD)
started several decades ago when it began providing healthcare
professionals and patients with innovative treatment solutions and
services. Philips' participation in the HOT-HMV study builds on the
company's global leadership in COPD management.
COPD is on the rise worldwide, estimated to become the third
leading cause of death in the next fifteen years, more than breast
cancer, colorectal cancer and prostate cancer combined1.
Moreover, the U.S. Center for Disease Control and Prevention (CDC)
estimates that caring for patients with these chronic conditions,
including COPD, accounts for 70 percent of the annual healthcare
spending in the United States
alone2.
The Philips-sponsored study researched the benefits of home
non-invasive ventilation (NIV), referred to as HMV in the study,
for patients with COPD. Initial results from this study, which will
be presented today at the European Respiratory Society (ERS)
International Congress, reveal that patients using HOT with HMV are
half as likely to be readmitted to the hospital. The HOT-HMV study
used a randomized controlled trial that compared the use of HMV and
HOT therapies with HOT alone in 116 patients with persistent
hypercapnia. Investigators included Dr. Nicholas Hart, Dr. Patrick Murphy and colleagues.
"Our goal with this study was to find a way to provide COPD
patients with oxygen therapy, as well as home ventilators, in
an effort to lower the number of patients being readmitted to
hospitals," said Dr. Nicholas Hart,
professor and clinical and academic director of Lane Fox
Respiratory Unit, St Thomas' Hospital. "The results of the HOT-HMV
study have the ability to change the way that COPD patients are
treated worldwide. We're looking forward to continuing the trial
over the next five years to monitor survival rates, which we hope
will rise, and readmission rates, which will hopefully fall."
"Philips is proud to be a lead sponsor of this study," said
Eli Diacopoulos, Business Leader,
Home Respiratory Care, Philips. "Managing COPD is more than simply
providing patients with respiratory devices, which is why Philips
continues to innovate and advance NIV therapies in the hospital and
home. It's about providing support across the entire continuum of
care, and Philips is uniquely positioned to make this a
reality."
In 2015, Philips funded and co-authored a retrospective study
that evaluated COPD patients who were hospitalized two or more
times within a year and transitioned to a COPD management program.
The results of the study showed that the readmission rate on
patients using NIV therapy in combination with a multifaceted
program of clinical support services was reduced by 88 percent
during the subsequent 12 months3.
Philips actively strives to help COPD patients in the home by
connecting the company's broad respiratory care portfolio – drug
delivery, oxygen therapy, telehealth and home ventilation. The
company continues to innovate and advance NIV therapies in the
hospital and home with its advanced therapy algorithms for COPD and
other chronic respiratory disorders.
To experience the entire portfolio of sleep and respiratory
products, visit Philips at booth B-07 at the European Respiratory
Society (ERS) International Congress 2016 in London (September 3-7). For updates on
Philips' presence at ERS 2016, visit http://philips.to/2b2GIEr. For
more information on Philips' advanced solutions for sleep and
respiratory care and updates from the show, visit @PhilipsResp and
follow #breatheinlife.
For further information, please contact:
Alicia Cafardi
Philips Group Communications
alicia.cafardi@philips.com
412-523-9616
About Royal
Philips
Royal Philips
(NYSE: PHG, AEX: PHIA) is a leading health technology company
focused on improving people's health and enabling better outcomes
across the health continuum from healthy living and prevention, to
diagnosis, treatment and home care. Philips leverages advanced
technology and deep clinical and consumer insights to deliver
integrated solutions. The company, headquartered in the Netherlands, is a leader in diagnostic
imaging, image-guided therapy, patient monitoring and health
informatics, as well as in consumer health and home care. Philips'
health technology portfolio generated 2015 sales of EUR 16.8 billion and employs approximately 69,000
employees with sales and services in more than 100 countries. News
about Philips can be found at www.philips.com/newscenter.
About Philips Respironics
Philips Respironics is a
global leader in the sleep and respiratory care markets, offering
solutions in sleep apnea management, oxygen therapy, noninvasive
ventilation and respiratory drug delivery. With more than 10 years
of cloud-based data sharing experience and analytics for more than
7 million patient lives, Philips Respironics has a long history of
leading new innovation in both devices and informatics solutions to
help patients sleep and breathe better.
1 World Health Organization. 2008. Retrieved from
http://www.who.int/respiratory/copd/burden/en/
2 Center for Disease Control. 2009. Retrieved
from
www.cdc.gov/chronicdisease/pdf/2009-power-of-prevention.pdf
3 Journal of Clinical Sleep Medicine. 2015.
Retrospective Assessment of Home Ventilation to Reduce
Rehospitalization in Chronic Obstructive Pulmonary Disease.
Retrieved from
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4442227/
Logo -
http://photos.prnewswire.com/prnh/20140122/NE50581LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/philips-sponsored-study-shows-great-promise-for-improving-quality-of-life-for-millions-of-patients-suffering-from-copd-300322516.html
SOURCE Royal Philips